Evidence map›Paper›PMID 24589670›Full record

SynthesisThe American journal of gastroenterology2014

The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America.

M Constanza Camargo, Apolinaria García, Arnoldo Riquelme, William Otero, Claudia A Camargo, Tomas Hernandez-García, Roberto Candia, Michael G Bruce, Charles S Rabkin

Registry-linked trialOpen access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The American journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05664685 (Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication), which is not on this map. Cited by 81 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 8 pooled it
19.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05664685 phase4completednot on this mapstarted 2022, after this paper: background citation

Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication: Clinical Efficacy Randomized Trial

TypeinterventionalSponsorPontificia Universidad Catolica de ChileRan2022 to 2024Enrolled127ConditionsHelicobacter Pylori InfectionArmsOptimized bismuth quadruple therapy, Control
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 8 syntheses or guidelines pooled it, 188 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Insights intoFrontiers in microbiology · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.The American journal of gastroenterology · 2017
    Guideline
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Prevalence of primaryGut microbes · 2026
    Review
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

M Constanza CamargoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
Apolinaria GarcíaDepartment of Microbiology, Universidad de Concepcion, Concepcion, Chile.
Arnoldo RiquelmeDepartment of Gastroenterology, School of Medicine, Pontificia Universidad Católica, Santiago, Chile.
William Otero1] Department of Gastroenterology, School of Medicine, Universidad Nacional, Bogota, Colombia [2] Clinica Fundadores, Bogotá, Colombia.
Claudia A CamargoSecretaría de Salud, México City, México.
Tomas Hernandez-GarcíaDepartment of Microbiology, Universidad de Concepcion, Concepcion, Chile.
Roberto CandiaDepartment of Gastroenterology, School of Medicine, Pontificia Universidad Católica, Santiago, Chile.
Michael G BruceDivision of Preparedness and Emerging Infections, Artic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.
Charles S RabkinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.
National Cancer Institute · USPontificia Universidad Católica de Chile · CLUniversity of Concepción · CLCenters for Disease Control and Prevention · USSecretaria de Salud · MXUniversidad Nacional de Colombia · CO

Funding

Molecular mechanisms of infection-related cancerZIACP010212 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2010 to 2025
$4.6M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

objectivesLatin America has a high prevalence of Helicobacter pylori infection and associated diseases, including gastric cancer. Antibiotic therapy can eradicate the bacterial infection and decrease associated morbidity and mortality. To tailor recommendations for optimal treatments, we summarized published literature and calculated region- and country-specific prevalences of antibiotic resistance.

methodsSearches of PubMed and regional databases for observational studies evaluating H. pylori antibiotic resistance yielded a total of 59 independent studies (56 in adults, 2 in children, and 1 in both groups) published up to October 2013 regarding H. pylori isolates collected between 1988 and 2011. Study-specific prevalences of primary resistance to commonly prescribed antibiotics were summarized using random-effects models. Between-study heterogeneity was assessed by meta-regression. As a sensitivity analysis, we extended our research to studies of patients with prior H. pylori-eradication therapy.

resultsSummary prevalences of antimicrobial primary resistance among adults varied by antibiotic, including 12% for clarithromycin (n=35 studies), 53% for metronidazole (n=34), 4% for amoxicillin (n=28), 6% for tetracycline (n=20), 3% for furazolidone (n=6), 15% for fluoroquinolones (n=5), and 8% for dual clarithromycin and metronidazole (n=10). Resistance prevalence varied significantly by country, but not by year of sample collection. Analyses including studies of patients with prior therapy yielded similar estimates. Pediatric reports were too few to be summarized by meta-analysis.

conclusionsResistance to first-line anti-H. pylori antibiotics is high in Latin American populations. In some countries, the empirical use of clarithromycin without susceptibility testing may not be appropriate. These findings stress the need for appropriate surveillance programs, improved antimicrobial regulations, and increased public awareness.

Indexed as

Drug Resistance, BacterialAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialHelicobacter InfectionsHelicobacter pyloriHumansLatin AmericaModels, StatisticalAnti-Bacterial Agents

Identifiers

PMID24589670
PMCPMC4268863
OpenAlexW1968884210

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.